{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"12","upperLimit":"727","value":"393.0"},{"groupId":"OG001","lowerLimit":"21","upperLimit":"693","value":"244.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"41"},{"groupId":"OG001","value":"40"}],"units":"Participants"}],"description":"SREs were defined according to the Bondronat SmPC to include radiotherapy to bone for treatment of fractures/impending fractures, surgery to bone for treatment of fractures, vertebral fractures, and non-vertebral fractures. Time to first SRE was defined as the time from first dose of study drug to the time of SRE during the study. The median time to first SRE was estimated by Kaplan-Meier analysis and expressed in days.","dispersionType":"Full Range","groups":[{"description":"Participants with multiple myeloma received ibandronate via 15-minute IV infusion as 6 mg every 4 weeks for up to 92 weeks. As a result of slow recruitment, the treatment duration was shortened to 40 weeks for participants who had not yet received 48 weeks of treatment. All participants returned for an additional follow-up observation 4 weeks after the end of treatment.","id":"OG000","title":"Ibandronate"},{"description":"Participants with multiple myeloma received zoledronate via 15-minute IV infusion as 4 mg every 4 weeks for up to 92 weeks. As a result of slow recruitment, the treatment duration was shortened to 40 weeks for participants who had not yet received 48 weeks of treatment. All participants returned for an additional follow-up observation 4 weeks after the end of treatment.","id":"OG001","title":"Zoledronate"}],"paramType":"MEDIAN","populationDescription":"ITT Population.","reportingStatus":"POSTED","timeFrame":"From Baseline to end of study (up to Week 96)","title":"Time to First SRE","type":"SECONDARY","unitOfMeasure":"days"}